What is Silence Therapeutics PLC (SLN) stock price today?

Silence Therapeutics PLC (SLN) currently trades at $7.31 per share. The stock has a market capitalization of $363.70M and a P/E ratio of —x.

Is SLN stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Silence Therapeutics PLC has a Smart Value Score of 17/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Silence Therapeutics PLC's revenue and earnings?

Silence Therapeutics PLC has trailing twelve-month (TTM) revenue of $559000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-1.89.

SLN

Silence Therapeutics PLC

NASDAQ: SLN · HEALTHCARE · BIOTECHNOLOGY

$7.31

+2.81% today

Updated 2026-04-30

Market cap

$363.70M

P/E ratio

—

P/S ratio

650.63x

EPS (TTM)

$-1.89

Dividend yield

—

52W range

$4 – $8

Volume

0.4M

Market cap

$363.70M

P/E ratio

—

P/S ratio

650.63x

EPS (TTM)

$-1.89

Dividend yield

—

52W range

$4 – $8

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$32.80

+348.70%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy0 Hold1 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-17.34M

- Revenue declining -99.90% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$21.66M	$25.38M	$43.26M	$559000.00	$559000.00
Net income	$-50.33M	$-43.27M	$-45.31M	$-88.61M	$-11.77M
EPS	—	—	—	—	$-1.89
Free cash flow	$-57.59M	$-39.40M	$-67.85M	$-46.38M	$-17.34M
Profit margin	-232.44%	-170.51%	-104.74%	-15,851.88%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SLN	$363.70M	17	2.7	2.5	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Silence Therapeutics PLC trades at $7.31. Our Smart Value Score of 17/100 indicates the stock is weak. TTM revenue stands at $559000.00.

Frequently asked questions

What is Silence Therapeutics PLC's stock price?

Silence Therapeutics PLC (SLN) trades at $7.31.

Is Silence Therapeutics PLC overvalued?

Smart Value Score 17/100 (Grade F, Strong Sell).

What is the price target of Silence Therapeutics PLC (SLN)?

The analyst target price is $32.80, representing +348.7% upside from the current price of $7.31.

What is Silence Therapeutics PLC's revenue?

TTM revenue is $559000.00.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio650.63x

ROE-90.30%

Beta1.33

50D MA$6.17

200D MA$5.91

Shares out0.05B

Float0.07B

Short ratio—

Avg volume0.4M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

SLN vs LLY →SLN vs JNJ →SLN vs ABBV →Stock screener →